Page last updated: 2024-11-07

ra 642

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RA 642: has central hypertensive properties; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124165
SCHEMBL ID9668239
MeSH IDM0056286

Synonyms (13)

Synonym
ra-642
2,2'-((4,8-bis(diethylamino)pyrimido(5,4-d)pyrimidine-2,6-diyl)bis((2-methoxyethyl)imino))bisethanol
ethanol, 2,2'-((4,8-bis(diethylamino)pyrimido(5,4-d)pyrimidine-2,6-diyl)bis((2-methoxyethyl)imino))bis-
ra 642bs
(2,2'-(4,8-bis(diethylamino)pyrimido(5,4-d)pyrimidine-2,6-diyl)di(2-methoxyethyl)imino)diethanol
ra 642
rxra 642
2-[[4,8-bis(diethylamino)-2-[2-hydroxyethyl(2-methoxyethyl)amino]pyrimido[5,4-d]pyrimidin-6-yl]-(2-methoxyethyl)amino]ethanol
54093-30-0
SCHEMBL9668239
DTXSID90202430
2,2'-((4,8-bis(diethylamino)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis((2-methoxyethyl)azanediyl))bis(ethan-1-ol)
AKOS040747340

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response and time-response curves were plotted for all compounds."( The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes.
Bellido, I; de la Cruz, JP; Sánchez de la Cuesta, F,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (57.89)18.7374
1990's8 (42.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.54 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]